Unknown

Dataset Information

0

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.


ABSTRACT: Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T-cell lymphomas, which is characterized by large pleomorphic cells with strong expression of CD30. Translocations involving ALK, the anaplastic lymphoma kinase gene, are associated with a favorable clinical outcome. Such ALK-positive ALCLs are usually responsive to a multidrug chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). However, there is no general consensus on the optimal therapy for relapsed or refractory ALCL. We report the case of a 24-year-old male suffering from ALK-positive ALCL with an uncommon manifestation of only extranodal disease in the gastric cardia region that showed primary refractoriness to standard CHOP chemotherapy. A combination therapy consisting of the anti-CD30 drug conjugate, brentuximab vedotin, and classical lymphoma salvage regimen DHAP (cisplatin, high-dose cytarabine and dexamethasone) was administered. Following two treatment cycles in 21-day intervals, the lymphoma showed considerable regression based on imaging diagnostics and no evidence of vital lymphoma in a subsequent biopsy. We did not observe any increase in toxicity; in particular, polyneuropathy and febrile neutropenia were not observed. In summary, we report that the antibody-drug conjugate brentuximab vedotin and a classical regimen used for aggressive lymphoma, DHAP, could be combined as salvage therapy in a case of refractory ALK-positive ALCL. Phase I/II studies will be required for safety and efficacy analysis.

SUBMITTER: Heidegger S 

PROVIDER: S-EPMC4074177 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.

Heidegger Simon S   Beer Ambros J AJ   Geissinger Eva E   Rosenwald Andreas A   Peschel Christian C   Ringshausen Ingo I   Keller Ulrich U  

OncoTargets and therapy 20140620


Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T-cell lymphomas, which is characterized by large pleomorphic cells with strong expression of CD30. Translocations involving ALK, the anaplastic lymphoma kinase gene, are associated with a favorable clinical outcome. Such ALK-positive ALCLs are usually responsive to a multidrug chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). However, there is no general consensus on  ...[more]

Similar Datasets

| S-EPMC10232850 | biostudies-literature
| S-EPMC8714712 | biostudies-literature
| S-EPMC5746164 | biostudies-literature
| S-EPMC3872218 | biostudies-other
| S-EPMC6935642 | biostudies-literature
| S-EPMC4827881 | biostudies-literature
| S-EPMC6084082 | biostudies-literature
| S-EPMC7102329 | biostudies-literature
| S-EPMC8018114 | biostudies-literature
| S-EPMC5855021 | biostudies-literature